# Avelumab in G2-3 NET

> **NCT03278379** · PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 17 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03278379
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2021-07-26
- **Final completion:** 2023-07-06
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278379, "Avelumab in G2-3 NET". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03278379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*